Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB

Cancer

Last data update: Mar 20, 2023. (Total: 58791 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 30 (of 47 Records)

Next

Query Trace: Lung Cancer[original query]>>Guidelines Related[Product Type]
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Isla Dolores et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2022
Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
Mitsudomi Tetsuya et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022
Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
Navani Neal et al. Lung cancer (Amsterdam, Netherlands) 2022 172142-153
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
R Teixeira Manuel et al. Acta medica portuguesa 2022
Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT).
Normanno Nicola et al. Cancers 2020 Jun 12(6)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
Ettinger David S et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 16(7) 807-821
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Oct
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai Pathmanathan et al. Lung cancer (Amsterdam, Netherlands) 2019 Aug 13665-73
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer Julie R et al. Journal for immunotherapy of cancer 2018 6(1) 75
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36715)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): Cetuximab (Erbitux) (L33278)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36499)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): Biomarker Testing for Neuroendocrine Tumors/Neoplasms (L37851)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (L37606)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (L37810)
The U.S. Centers for Medicare & Medicaid Services
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Gubens Matthew A et al. Journal of the National Comprehensive Cancer Network : JNCCN 2019 May 17(5.5) 574-578
[EGFR-TKI ADR Management Chinese Expert Consensus].
et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2019 Feb 22(2) 57-81
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.
Prabhash Kumar et al. South Asian journal of cancer 8(1) 1-17
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Akamatsu Hiroaki et al. International journal of clinical oncology 2019 Jul 24(7) 731-770
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
Garrido Pilar et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2012 May 14(5) 338-49
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.
Leighl Natasha B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Nov 32(32) 3673-9
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman Neal I et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 13(3) 323-358
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Socinski Mark A et al. Chest 2013 May 143(5 Suppl) e341S-e368S
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Lindeman Neal I et al. The Journal of molecular diagnostics : JMD 2013 Jul 15(4) 415-53
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
Prabhash Kumar et al. Advances in therapy 2019 Mar
IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
Rolfo Christian et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Jun
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy.
Copur Mehmet Sitki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 May JCO2018788240
Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.
Stockley T et al. Current oncology (Toronto, Ont.) 2018 Apr 25(2) 163-169
Standardizing biomarker testing for Canadian patients with advanced lung cancer.
Melosky B et al. Current oncology (Toronto, Ont.) 2018 Feb 25(1) 73-82
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.
Odogwu Lauretta et al. The oncologist 2018 Feb
TOP